Innovation within the implantable device industry, including cardiac, orthopedic and soft-tissue implants, has grown tremendously in recent years to meet market need. In fact, it is projected that the use of cardiac implantable devices will nearly double by 2020. While these devices have immeasurably improved the lives of patients, they also pose a serious risk for infection. Whenever you introduce a foreign material into the body, you also introduce the risk of that material becoming colonized with microbes on its surface, which can lead to infection.
With the increased focus on lowering infection rates in hospitals, and the growing concern of healthcare-associated infections (HAIs) caused by antibiotic-resistant bacteria, device manufacturers are designing their products to incorporate Sciessent’s Agion® Antimicrobial technology to do their part in the fight. As regulations and reimbursement continue to change, healthcare facilities are seeing the value in making upfront investments in products that will save them lives, time and money down the road.
Agion-embedded permanent implants resist the growth and spread of microbes on device surfaces. The smart technology is designed to automatically release its antimicrobial components only when conditions for microbial growth are present, resulting in long-lasting protection against microbes. And Agion has been shown in laboratory studies to be highly effective against antibiotic resistant bacteria.
For more information about Sciessent and how we can improve your implantable devices, please feel free to contact us.
The Agion® Antimicrobial is presently registered by the United States Environmental Protection Agency as a preservative and bacteriostatic agent for use in treated articles under 40 CFR 152.25a. The information presented herein is not intended to support or endorse public health claims for treated articles. The Agion Antimicrobial is also used in medical devices under the Food and Drug Administration in the US; those medical device claims are based on safety and efficacy testing and are limited to those approved by FDA. In the EU, the Agion Antimicrobial is used in medical devices under the Medical Device Directive: those medical device claims are based on safety and efficacy testing and are limited to those approved by the designated Competent Authorities and/or Notified Bodies.